Atlas Trials

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

Clinical trial NCT03085173 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03085173
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Chronic Lymphocytic Leukemia (CLL)RelapsedRefractory
Start date
2017-03-15
Primary completion
2027-03-01
Enrollment
39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.